Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Huang‐Chih Chang,Chin‐Chou Wang,Chia‐Cheng Tseng,Kuo‐Tung Huang,Yu‐Mu Chen,Yu‐Ping Chang,Chien‐Hao Lai,Wen‐Feng Fang,Meng‐Chih Lin,Hung‐Yi Chuang
DOI: https://doi.org/10.1111/1759-7714.15111
IF: 3.223
2023-09-23
Thoracic Cancer
Abstract:Predictors of first‐line epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) outcomes? The aim of this network meta‐analysis was to compare survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC. Eleven real‐world observational studies were included. This NMA suggests that afatinib results in longer progression‐free survival (PFS) in EGFR L858R and EGFR Del19 mutations, longer PFS than gefitinib in patients with brain metastasis and longer PFS than gefitinib in patients with ECOG status 0–1. Background Despite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients' clinical characteristics. This network meta‐analysis (NMA) compared survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC. Methods This NMA included real‐world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types. Results In patients with the EGFR L858R mutation, afatinib resulted in significantly longer progression‐free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46–0.75) and gefitinib (HR: 0.41, 95% CI: 0.32–0.53). Similarly, in patients with the EGFR Del19 mutation, afatinib and erlotinib resulted in significantly longer PFS than gefitinib (HR: 0.48 with 95% CI: 0.33–0.71 and HR: 0.54 with 95% CI: 0.36–0.80, respectively). Moreover, afatinib resulted in significantly longer PFS than gefitinib in patients with brain metastasis (HR: 0.53, 95% CI: 0.33–0.87) or ECOG status 0–1 (HR: 0.37, 95% CI: 0.23–0.59). Conclusion This NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis.
oncology,respiratory system
What problem does this paper attempt to address?